Otis M. Davis

Researcher

University of Arkansas for Medical Sciences

unknown

2 h-index 4 pubs 16 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Otis M. Davis's research focuses on the comparative pharmacological effects of antiplatelet medications in patients with advanced chronic kidney disease (CKD). His work investigates the efficacy of ticagrelor versus clopidogrel in inhibiting platelet aggregation and reducing inflammatory burden in individuals with stages 4 or 5 CKD. Davis has also published on the relationship between platelet count, platelet volume, and CKD status. His recent publications include studies examining ticagrelor's superiority over clopidogrel and a response to a discussion on SGLT-2 inhibitor use in CKD. Davis has a h-index of 2 with 16 total citations across 4 publications. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Nishank Jain, Jerry Ware, Yasir Rahmatallah, and Adam Corken, with whom he shares multiple publications.

Metrics

  • h-index: 2
  • Publications: 4
  • Citations: 16

Selected Publications

  • Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD] (2024) DOI
  • Platelet Count and Platelet Volume in Patients with CKD (2023) DOI
  • Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease (2023) DOI
  • Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD (2022) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics